With　the　rapid　development　of　drug　delivery　systems,　extracellular　vesicles　(EVs)　have　emerged　as　promising　stars　for　improving　targeting　abilities　and　realizing　effective　delivery.　Numerous　studies　have　shown　when　compared　to　conventional　strategies　in　targeted　drug　delivery　(TDD),　EVs-based　strategies　have　several　distinguished　advantages　besides　targeting,　such　as　participating　in　cell-to-cell　communications　and　immune　response,　showing　high　biocompatibility　and　stability,　penetrating　through　biological　barriers,　etc.　In　this　review,　we　mainly　focus　on　the　mass　production　of　EVs　including　the　challenges　and　strategies　for　scaling　up　EVs　production　in　a　cost-effective　and　reproducible　manner,　the　loading　and　active　targeting　methods,　and　examples　of　EVs　as　vehicles　for　TDD　in　consideration　of　potential　safety　and　regulatory　issues　associated.　We　also　conclude　and　discuss　the　rigor　and　reproducibility　of　EVs　production,　the　current　research　status　of　the　application　of　EVs-based　strategies　to　targeted　drug　delivery,　clinical　conversion　prospects,　and　existing　chances　and　challenges.